• Category: Pharma
  • Investment Status: Advanced
  • Medical Field: Lipids
  • Patent Status: Provisional
  • Development Status: in vivo studies, formulation, phase 2 clinical study
  • Medical Center: HaSharon Medical Center
  • Inventors: Dr Dror Robinson

CannaLean is a company committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from dyslipidemia. Cannalean has completed various in vivo studies showing a significant decrease in cholesterol / triglyceride blood levels, demonstrating the potential clinical effect of the novel patent-protected formulation.

A novel formulation of a synthetic form of Cannabidiol (CBD), a non-psychotropic component of Cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to significantly reduce lipid blood levels.

Low intestinal absorption is a major problem with oral CBD administration. The chitosan particle acts as a solvent of the CBD allowing better interaction with the intestinal cells membrane and higher absorption. The improved absorption allows lowering of the required dose to achieve an effect. In addition venous drainage from the intestine allows direct effect on the liver to decrease cholesterol synthesis.

Our preliminary in vivo results in Guinea pig and rat models show the effect of the novel formulation on cholesterol and triglycerides reduction, as compared to controls and each compound alone. The triglycerides/ HDL ratio, which is thought to predict extensive coronary disease  were also decreased.